Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants
As the coronavirus disease 2019 (COVID-19) pandemic continues to claim thousands of lives daily around the world, the pathogen responsible for it, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to undergo mutational changes. A recent paper in the journal
Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur.
The SARS-CoV-2 501Y.V2 variant
The constant occurrence of mutations in the various regions of the viral genome has led to the emergence of a multitude of variants, some of which have become global variants of concern (VOCs).

Related Keywords

South Africa ,South African ,Oxford Astrazeneca ,Liji Thomas ,Pfizer ,Alexander Limbach ,Antibodies ,Sars ,Sars Cov 2 ,Ace2 ,Angiotensin ,Angiotensin Converting Enzyme 2 ,Antibody ,Cell ,Convalescent Plasma ,Corona Virus ,Coronavirus Disease Covid 19 ,Efficacy ,Enzyme ,Genome ,Genomic ,Genomic Sequencing ,Homologous ,Mutation ,Pandemic ,Pathogen ,Receptor ,Respiratory ,Severe Acute Respiratory ,Severe Acute Respiratory Syndrome ,Syndrome ,Vaccine ,Virus ,ஃபைசர் ,அலெக்சாண்டர் லிம்பாக் ,ஆன்டிபாடிகள் ,சர்ச் ,ஆன்டிபாடி ,செல் ,சுறுசுறுப்பான பிளாஸ்மா ,கொரோனா வைரஸ் ,நொதி ,மரபணு ,பிறழ்வு ,சர்வதேச பரவல் ,நோய்க்கிருமி ,ஏற்பி ,சுவாச ,கடுமையானது எடுப்போசை சுவாச ,கடுமையானது எடுப்போசை சுவாச நோய்க்குறி ,நோய்க்குறி ,தடுப்பூசி ,வைரஸ் ,